Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) Total Equity: ¥485.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BJSE:920367 Jiangxi Xinganjiang Pharmaceutical Co Ltd BJSE:920367
53 GF Score
Price ¥31.00
GF Value ¥12.04
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Jiangxi Xinganjiang Pharmaceutical Co Total Equity?

Jiangxi Xinganjiang Pharmaceutical Co BJSE:920367 53 Total Equity is ¥485.2 Mil as of Mar. 2026. GuruFocus rates BJSE:920367 with a GF Score™ of 53/100 and a GF Value™ of ¥12.04 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Jiangxi Xinganjiang Pharmaceutical Co's total equity for the quarter that ended in Mar. 2026 was ¥485.2 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Jiangxi Xinganjiang Pharmaceutical Co Total Equity Historical Data

* Premium members only.

The historical data trend for Jiangxi Xinganjiang Pharmaceutical Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangxi Xinganjiang Pharmaceutical Co Total Equity Chart

Jiangxi Xinganjiang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 236.54 282.69 473.73 476.58 482.54

Jiangxi Xinganjiang Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 481.88 476.03 476.81 482.54 485.23
BJSE:920367
53GF Score
Jiangxi Xinganjiang Pharmaceutical Co Ltd BJSE:920367
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangxi Xinganjiang Pharmaceutical Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Jiangxi Xinganjiang Pharmaceutical Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=574.139-91.602
=482.5

Jiangxi Xinganjiang Pharmaceutical Co's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=591.856-106.63
=485.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ¥485.2 Mil mean?
Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) has a Total Equity of ¥485.2 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Jiangxi Xinganjiang Pharmaceutical Co and its competitors.
Is Jiangxi Xinganjiang Pharmaceutical Co's Total Equity too high?
Jiangxi Xinganjiang Pharmaceutical Co's current Total Equity is ¥485.2 Mil. Overall, Jiangxi Xinganjiang Pharmaceutical Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Xinganjiang Pharmaceutical Co's Total Equity compare to ZTS and UTHR?
Jiangxi Xinganjiang Pharmaceutical Co's Total Equity of ¥485.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Jiangxi Xinganjiang Pharmaceutical Co and its competitors. Jiangxi Xinganjiang Pharmaceutical Co's current Total Equity is ¥485.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Xinganjiang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥12.04, compared to a current price of ¥31.00 — trading 157.5% above its estimated fair value. The current Total Equity is ¥485.2 Mil. Jiangxi Xinganjiang Pharmaceutical Co's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367), the current Total Equity is ¥485.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangxi Xinganjiang Pharmaceutical Co (BJSE:920367) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangxi Xinganjiang Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥31.00 is trading 157.5% above its estimated GF Value™ of ¥12.04. GuruFocus considers Jiangxi Xinganjiang Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for BJSE:920367:

  • Total Equity: ¥485.2 Mil
  • GF Value™: ¥12.04 vs. price of ¥31.00 (157.5% above fair value)
  • GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the BJSE:920367 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jiangxi Xinganjiang Pharmaceutical Co Business Description

Address No. 36 Yunzhang Road, Industrial Park, Jizhou District, Jiangxi Province, Ji'an City, CHN, 343000
Jiangxi Xinganjiang Pharmaceutical Co Ltd conducts research and development, production, and sales of chemical raw materials, chemical preparations, and Chinese patent medicines. The company's raw material medicine products are mainly calcium gluconate, zinc gluconate, ferrous gluconate, and other gluconate series raw material medicines. Its main chemical preparations are vitamin C chewable tablets and compound Yinqiao aminomin capsules, and Phenaminokamin Tablets.
53GF Score

Get the complete analysis for BJSE:920367

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥31.00
Price
¥12.04
GF Value